Laboratory for Clinical Chemistry and Hematology, UMC Utrecht, Utrecht, The Netherlands.
PLoS One. 2013 Apr 22;8(4):e62080. doi: 10.1371/journal.pone.0062080. Print 2013.
Cardiovascular disease is one of the major causes of death worldwide. Assessing the risk for cardiovascular disease is an important aspect in clinical decision making and setting a therapeutic strategy, and the use of serological biomarkers may improve this. Despite an overwhelming number of studies and meta-analyses on biomarkers and cardiovascular disease, there are no comprehensive studies comparing the relevance of each biomarker. We performed a systematic review of meta-analyses on levels of serological biomarkers for atherothrombosis to compare the relevance of the most commonly studied biomarkers.
Medline and Embase were screened on search terms that were related to "arterial ischemic events" and "meta-analyses". The meta-analyses were sorted by patient groups without pre-existing cardiovascular disease, with cardiovascular disease and heterogeneous groups concerning general populations, groups with and without cardiovascular disease, or miscellaneous. These were subsequently sorted by end-point for cardiovascular disease or stroke and summarized in tables. We have identified 85 relevant full text articles, with 214 meta-analyses. Markers for primary cardiovascular events include, from high to low result: C-reactive protein, fibrinogen, cholesterol, apolipoprotein B, the apolipoprotein A/apolipoprotein B ratio, high density lipoprotein, and vitamin D. Markers for secondary cardiovascular events include, from high to low result: cardiac troponins I and T, C-reactive protein, serum creatinine, and cystatin C. For primary stroke, fibrinogen and serum uric acid are strong risk markers. Limitations reside in that there is no acknowledged search strategy for prognostic studies or meta-analyses.
For primary cardiovascular events, markers with strong predictive potential are mainly associated with lipids. For secondary cardiovascular events, markers are more associated with ischemia. Fibrinogen is a strong predictor for primary stroke.
心血管疾病是全球主要死亡原因之一。评估心血管疾病风险是临床决策和制定治疗策略的重要方面,而血清生物标志物的使用可能会改善这一点。尽管有大量关于生物标志物和心血管疾病的研究和荟萃分析,但没有全面的研究比较每种生物标志物的相关性。我们对动脉粥样硬化的血清生物标志物的荟萃分析进行了系统回顾,以比较最常研究的生物标志物的相关性。
使用与“动脉缺血性事件”和“荟萃分析”相关的搜索词对 Medline 和 Embase 进行了筛选。根据无预先存在的心血管疾病、有心血管疾病和一般人群的混杂组、有和无心血管疾病的组或其他组,对荟萃分析进行了分类。然后,根据心血管疾病或中风的终点对这些分类进行了排序,并汇总在表格中。我们已经确定了 85 篇相关的全文文章,其中有 214 篇荟萃分析。用于主要心血管事件的标志物包括:C 反应蛋白、纤维蛋白原、胆固醇、载脂蛋白 B、载脂蛋白 A/载脂蛋白 B 比值、高密度脂蛋白和维生素 D,从高到低排列。用于二级心血管事件的标志物包括:心肌肌钙蛋白 I 和 T、C 反应蛋白、血清肌酐和胱抑素 C,从高到低排列。对于原发性中风,纤维蛋白原和血清尿酸是强烈的风险标志物。局限性在于,没有公认的用于预后研究或荟萃分析的搜索策略。
对于主要心血管事件,具有较强预测潜力的标志物主要与脂质相关。对于二级心血管事件,标志物更与缺血相关。纤维蛋白原是原发性中风的强烈预测因子。